nodes	percent_of_prediction	percent_of_DWPC	metapath
Pyrazinamide—AOX1—Methotrexate—muscle cancer	0.331	0.376	CbGbCtD
Pyrazinamide—XDH—Doxorubicin—muscle cancer	0.296	0.336	CbGbCtD
Pyrazinamide—CYP1A2—Dacarbazine—muscle cancer	0.115	0.131	CbGbCtD
Pyrazinamide—CYP1A2—Etoposide—muscle cancer	0.0565	0.0641	CbGbCtD
Pyrazinamide—AOX1—Effects of Nitric Oxide—MB—muscle cancer	0.0384	0.468	CbGpPWpGaD
Pyrazinamide—XDH—Effects of Nitric Oxide—MB—muscle cancer	0.0357	0.435	CbGpPWpGaD
Pyrazinamide—CYP3A4—Vincristine—muscle cancer	0.0323	0.0366	CbGbCtD
Pyrazinamide—CYP3A4—Etoposide—muscle cancer	0.0296	0.0336	CbGbCtD
Pyrazinamide—CYP3A4—Doxorubicin—muscle cancer	0.0202	0.0229	CbGbCtD
Pyrazinamide—Hepatomegaly—Dactinomycin—muscle cancer	0.00165	0.0449	CcSEcCtD
Pyrazinamide—Hepatotoxicity—Dactinomycin—muscle cancer	0.00151	0.0411	CcSEcCtD
Pyrazinamide—Coagulopathy—Dactinomycin—muscle cancer	0.0015	0.0408	CcSEcCtD
Pyrazinamide—AOX1—Tryptophan metabolism—MDM2—muscle cancer	0.00124	0.0151	CbGpPWpGaD
Pyrazinamide—Hyperuricaemia—Vincristine—muscle cancer	0.00112	0.0306	CcSEcCtD
Pyrazinamide—Hepatotoxicity—Etoposide—muscle cancer	0.00109	0.0298	CcSEcCtD
Pyrazinamide—Blood uric acid increased—Vincristine—muscle cancer	0.00106	0.0289	CcSEcCtD
Pyrazinamide—Hyperuricaemia—Etoposide—muscle cancer	0.000911	0.0248	CcSEcCtD
Pyrazinamide—Blood uric acid increased—Etoposide—muscle cancer	0.00086	0.0234	CcSEcCtD
Pyrazinamide—Rash maculo-papular—Etoposide—muscle cancer	0.000768	0.0209	CcSEcCtD
Pyrazinamide—AOX1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—muscle cancer	0.000719	0.00877	CbGpPWpGaD
Pyrazinamide—XDH—Selenium Micronutrient Network—PTGS2—muscle cancer	0.000662	0.00808	CbGpPWpGaD
Pyrazinamide—Hepatotoxicity—Methotrexate—muscle cancer	0.000655	0.0178	CcSEcCtD
Pyrazinamide—Hepatomegaly—Doxorubicin—muscle cancer	0.000619	0.0169	CcSEcCtD
Pyrazinamide—Dysuria—Vincristine—muscle cancer	0.000612	0.0167	CcSEcCtD
Pyrazinamide—Photosensitivity reaction—Vincristine—muscle cancer	0.000597	0.0163	CcSEcCtD
Pyrazinamide—Hepatitis—Dactinomycin—muscle cancer	0.000586	0.016	CcSEcCtD
Pyrazinamide—CYP1A2—Melatonin metabolism and effects—FOXO1—muscle cancer	0.000585	0.00714	CbGpPWpGaD
Pyrazinamide—Hyperuricaemia—Methotrexate—muscle cancer	0.000546	0.0148	CcSEcCtD
Pyrazinamide—Blood uric acid increased—Methotrexate—muscle cancer	0.000515	0.014	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Dactinomycin—muscle cancer	0.000474	0.0129	CcSEcCtD
Pyrazinamide—Hyperuricaemia—Doxorubicin—muscle cancer	0.000472	0.0129	CcSEcCtD
Pyrazinamide—Malaise—Dactinomycin—muscle cancer	0.00046	0.0125	CcSEcCtD
Pyrazinamide—Blood uric acid increased—Doxorubicin—muscle cancer	0.000446	0.0121	CcSEcCtD
Pyrazinamide—Myalgia—Dactinomycin—muscle cancer	0.000435	0.0118	CcSEcCtD
Pyrazinamide—Discomfort—Dactinomycin—muscle cancer	0.000429	0.0117	CcSEcCtD
Pyrazinamide—Photosensitivity—Methotrexate—muscle cancer	0.000418	0.0114	CcSEcCtD
Pyrazinamide—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000418	0.00509	CbGpPWpGaD
Pyrazinamide—Thrombocytopenia—Dactinomycin—muscle cancer	0.000408	0.0111	CcSEcCtD
Pyrazinamide—Rash maculo-papular—Doxorubicin—muscle cancer	0.000398	0.0108	CcSEcCtD
Pyrazinamide—AOX1—Metabolism—FH—muscle cancer	0.000397	0.00484	CbGpPWpGaD
Pyrazinamide—Anorexia—Dactinomycin—muscle cancer	0.000397	0.0108	CcSEcCtD
Pyrazinamide—Myalgia—Vincristine—muscle cancer	0.000388	0.0106	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.000379	0.0103	CcSEcCtD
Pyrazinamide—XDH—Metabolism—FH—muscle cancer	0.000369	0.0045	CbGpPWpGaD
Pyrazinamide—Thrombocytopenia—Vincristine—muscle cancer	0.000364	0.00992	CcSEcCtD
Pyrazinamide—Photosensitivity—Doxorubicin—muscle cancer	0.000362	0.00986	CcSEcCtD
Pyrazinamide—Decreased appetite—Dactinomycin—muscle cancer	0.000362	0.00985	CcSEcCtD
Pyrazinamide—Anorexia—Vincristine—muscle cancer	0.000355	0.00965	CcSEcCtD
Pyrazinamide—Feeling abnormal—Dactinomycin—muscle cancer	0.000343	0.00934	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Etoposide—muscle cancer	0.000343	0.00933	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Vincristine—muscle cancer	0.000339	0.00923	CcSEcCtD
Pyrazinamide—Malaise—Etoposide—muscle cancer	0.000333	0.00907	CcSEcCtD
Pyrazinamide—Body temperature increased—Dactinomycin—muscle cancer	0.000329	0.00896	CcSEcCtD
Pyrazinamide—Decreased appetite—Vincristine—muscle cancer	0.000324	0.0088	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Vincristine—muscle cancer	0.000321	0.00874	CcSEcCtD
Pyrazinamide—Discomfort—Etoposide—muscle cancer	0.000311	0.00846	CcSEcCtD
Pyrazinamide—Hypersensitivity—Dactinomycin—muscle cancer	0.000307	0.00835	CcSEcCtD
Pyrazinamide—Dysuria—Methotrexate—muscle cancer	0.000297	0.00808	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Etoposide—muscle cancer	0.000295	0.00803	CcSEcCtD
Pyrazinamide—Body temperature increased—Vincristine—muscle cancer	0.000294	0.00801	CcSEcCtD
Pyrazinamide—Photosensitivity reaction—Methotrexate—muscle cancer	0.00029	0.00789	CcSEcCtD
Pyrazinamide—Anorexia—Etoposide—muscle cancer	0.000287	0.00782	CcSEcCtD
Pyrazinamide—Hypersensitivity—Vincristine—muscle cancer	0.000274	0.00746	CcSEcCtD
Pyrazinamide—Vomiting—Dactinomycin—muscle cancer	0.000265	0.00721	CcSEcCtD
Pyrazinamide—Rash—Dactinomycin—muscle cancer	0.000263	0.00715	CcSEcCtD
Pyrazinamide—Decreased appetite—Etoposide—muscle cancer	0.000262	0.00713	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Etoposide—muscle cancer	0.00026	0.00708	CcSEcCtD
Pyrazinamide—Dysuria—Doxorubicin—muscle cancer	0.000257	0.007	CcSEcCtD
Pyrazinamide—Hepatitis—Methotrexate—muscle cancer	0.000254	0.00692	CcSEcCtD
Pyrazinamide—Photosensitivity reaction—Doxorubicin—muscle cancer	0.000251	0.00683	CcSEcCtD
Pyrazinamide—Feeling abnormal—Etoposide—muscle cancer	0.000248	0.00676	CcSEcCtD
Pyrazinamide—Nausea—Dactinomycin—muscle cancer	0.000247	0.00673	CcSEcCtD
Pyrazinamide—AOX1—Disease—ENO2—muscle cancer	0.000244	0.00298	CbGpPWpGaD
Pyrazinamide—CYP1A2—Tryptophan metabolism—MDM2—muscle cancer	0.000243	0.00296	CbGpPWpGaD
Pyrazinamide—Urticaria—Etoposide—muscle cancer	0.000239	0.00652	CcSEcCtD
Pyrazinamide—Body temperature increased—Etoposide—muscle cancer	0.000238	0.00649	CcSEcCtD
Pyrazinamide—Vomiting—Vincristine—muscle cancer	0.000237	0.00644	CcSEcCtD
Pyrazinamide—Rash—Vincristine—muscle cancer	0.000235	0.00639	CcSEcCtD
Pyrazinamide—Dermatitis—Vincristine—muscle cancer	0.000234	0.00638	CcSEcCtD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—muscle cancer	0.000234	0.00285	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—MED12—muscle cancer	0.000224	0.00274	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—HMGA1—muscle cancer	0.000222	0.00271	CbGpPWpGaD
Pyrazinamide—Hypersensitivity—Etoposide—muscle cancer	0.000222	0.00604	CcSEcCtD
Pyrazinamide—Nausea—Vincristine—muscle cancer	0.000221	0.00602	CcSEcCtD
Pyrazinamide—Hepatitis—Doxorubicin—muscle cancer	0.00022	0.00599	CcSEcCtD
Pyrazinamide—CYP1A2—Arachidonic acid metabolism—PTGS2—muscle cancer	0.000219	0.00267	CbGpPWpGaD
Pyrazinamide—Pruritus—Etoposide—muscle cancer	0.000213	0.0058	CcSEcCtD
Pyrazinamide—XDH—Metabolism—MED12—muscle cancer	0.000209	0.00254	CbGpPWpGaD
Pyrazinamide—Ill-defined disorder—Methotrexate—muscle cancer	0.000205	0.00559	CcSEcCtD
Pyrazinamide—AOX1—Metabolism—ENO2—muscle cancer	0.000205	0.00249	CbGpPWpGaD
Pyrazinamide—Malaise—Methotrexate—muscle cancer	0.0002	0.00543	CcSEcCtD
Pyrazinamide—AOX1—Disease—FOXO4—muscle cancer	0.000199	0.00243	CbGpPWpGaD
Pyrazinamide—Vomiting—Etoposide—muscle cancer	0.000192	0.00522	CcSEcCtD
Pyrazinamide—XDH—Metabolism—ENO2—muscle cancer	0.00019	0.00232	CbGpPWpGaD
Pyrazinamide—Rash—Etoposide—muscle cancer	0.00019	0.00517	CcSEcCtD
Pyrazinamide—Dermatitis—Etoposide—muscle cancer	0.00019	0.00517	CcSEcCtD
Pyrazinamide—Arthralgia—Methotrexate—muscle cancer	0.000188	0.00513	CcSEcCtD
Pyrazinamide—Myalgia—Methotrexate—muscle cancer	0.000188	0.00513	CcSEcCtD
Pyrazinamide—CYP3A4—Tryptophan metabolism—MDM2—muscle cancer	0.000187	0.00228	CbGpPWpGaD
Pyrazinamide—Discomfort—Methotrexate—muscle cancer	0.000186	0.00506	CcSEcCtD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	0.000184	0.00225	CbGpPWpGaD
Pyrazinamide—Nausea—Etoposide—muscle cancer	0.000179	0.00487	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Doxorubicin—muscle cancer	0.000178	0.00484	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Methotrexate—muscle cancer	0.000177	0.00481	CcSEcCtD
Pyrazinamide—Malaise—Doxorubicin—muscle cancer	0.000173	0.0047	CcSEcCtD
Pyrazinamide—Anorexia—Methotrexate—muscle cancer	0.000172	0.00468	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.000165	0.00448	CcSEcCtD
Pyrazinamide—Arthralgia—Doxorubicin—muscle cancer	0.000163	0.00444	CcSEcCtD
Pyrazinamide—Myalgia—Doxorubicin—muscle cancer	0.000163	0.00444	CcSEcCtD
Pyrazinamide—Discomfort—Doxorubicin—muscle cancer	0.000161	0.00439	CcSEcCtD
Pyrazinamide—Dyspepsia—Methotrexate—muscle cancer	0.000159	0.00433	CcSEcCtD
Pyrazinamide—Decreased appetite—Methotrexate—muscle cancer	0.000157	0.00427	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Methotrexate—muscle cancer	0.000156	0.00424	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Doxorubicin—muscle cancer	0.000153	0.00417	CcSEcCtD
Pyrazinamide—Anorexia—Doxorubicin—muscle cancer	0.000149	0.00406	CcSEcCtD
Pyrazinamide—Feeling abnormal—Methotrexate—muscle cancer	0.000149	0.00405	CcSEcCtD
Pyrazinamide—AOX1—Disease—FOXO1—muscle cancer	0.000147	0.00179	CbGpPWpGaD
Pyrazinamide—Urticaria—Methotrexate—muscle cancer	0.000143	0.0039	CcSEcCtD
Pyrazinamide—Body temperature increased—Methotrexate—muscle cancer	0.000143	0.00388	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.000142	0.00388	CcSEcCtD
Pyrazinamide—Dyspepsia—Doxorubicin—muscle cancer	0.000138	0.00375	CcSEcCtD
Pyrazinamide—Decreased appetite—Doxorubicin—muscle cancer	0.000136	0.0037	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000135	0.00367	CcSEcCtD
Pyrazinamide—Hypersensitivity—Methotrexate—muscle cancer	0.000133	0.00362	CcSEcCtD
Pyrazinamide—Feeling abnormal—Doxorubicin—muscle cancer	0.000129	0.00351	CcSEcCtD
Pyrazinamide—Pruritus—Methotrexate—muscle cancer	0.000128	0.00348	CcSEcCtD
Pyrazinamide—Urticaria—Doxorubicin—muscle cancer	0.000124	0.00338	CcSEcCtD
Pyrazinamide—Body temperature increased—Doxorubicin—muscle cancer	0.000124	0.00336	CcSEcCtD
Pyrazinamide—Hypersensitivity—Doxorubicin—muscle cancer	0.000115	0.00313	CcSEcCtD
Pyrazinamide—Vomiting—Methotrexate—muscle cancer	0.000115	0.00312	CcSEcCtD
Pyrazinamide—Rash—Methotrexate—muscle cancer	0.000114	0.0031	CcSEcCtD
Pyrazinamide—Dermatitis—Methotrexate—muscle cancer	0.000114	0.0031	CcSEcCtD
Pyrazinamide—AOX1—Disease—KIT—muscle cancer	0.000112	0.00137	CbGpPWpGaD
Pyrazinamide—Pruritus—Doxorubicin—muscle cancer	0.000111	0.00301	CcSEcCtD
Pyrazinamide—Nausea—Methotrexate—muscle cancer	0.000107	0.00292	CcSEcCtD
Pyrazinamide—Vomiting—Doxorubicin—muscle cancer	9.94e-05	0.00271	CcSEcCtD
Pyrazinamide—Rash—Doxorubicin—muscle cancer	9.86e-05	0.00268	CcSEcCtD
Pyrazinamide—CYP1A2—Metabolism of lipids and lipoproteins—MED12—muscle cancer	9.86e-05	0.0012	CbGpPWpGaD
Pyrazinamide—Dermatitis—Doxorubicin—muscle cancer	9.85e-05	0.00268	CcSEcCtD
Pyrazinamide—Nausea—Doxorubicin—muscle cancer	9.29e-05	0.00253	CcSEcCtD
Pyrazinamide—AOX1—Disease—MDM2—muscle cancer	8.83e-05	0.00108	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—PTGS2—muscle cancer	8.51e-05	0.00104	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—FH—muscle cancer	7.77e-05	0.000947	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—PTGS2—muscle cancer	7.13e-05	0.000869	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—PTGS2—muscle cancer	6.63e-05	0.000808	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—FH—muscle cancer	6e-05	0.000731	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—MED12—muscle cancer	4.39e-05	0.000535	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—ENO2—muscle cancer	4e-05	0.000488	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—MED12—muscle cancer	3.39e-05	0.000413	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	3.13e-05	0.000382	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—ENO2—muscle cancer	3.09e-05	0.000377	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—PTGS2—muscle cancer	1.39e-05	0.00017	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—PTGS2—muscle cancer	1.08e-05	0.000131	CbGpPWpGaD
